MarginScan is proposed to be used to support Mohs micrographic surgery procedures for skin cancer treatment
The partnership will combine PHC's manufacturing capabilities with NovaScan's technology to detect carcinoma tissue. (Credit: National Cancer Institute on Unsplash)
Japan-based PHC and NovaScan have entered into a partnership to assess the feasibility of MarginScan, the latter’s investigational ex vivo medical device, in non-melanoma skin cancer (NMSC) detection.
Under the partnership, the companies will jointly study MarginScan’s feasibility for a comprehensive real-time margin detection for NMSC.
NovaScan said that the device is proposed to be used to support Mohs micrographic surgery procedures for the treatment of skin cancer. MarginScan can lower patient morbidity and enhance outcomes for patients as well as clinicians, said the US-based clinical stage oncology company.
PHC in vitro diagnostics division director Hiroyuki Tokunaga said: “We look forward to collaborating with NovaScan to provide high-value-added solutions in the pathology diagnostics field, leveraging our expertise in highly reliable medical device development.
“PHC is also committed to accelerating the development of point-of-care technology that enables highly convenient testing, to contribute to our mission of improving the quality of healthcare around the world.”
The collaboration will combine PHC’s manufacturing capabilities with NovaScan’s advanced technology for identifying carcinoma tissue.
The two firms will also investigate other potential alliances to offer new value to patients and healthcare professionals in the field of oncology.
NovaScan CEO Craig Davis said: “We are positively thrilled to be collaborating with PHC Group, a world class provider of oncology diagnostics solutions and medical devices.
“Our platform technology enables in vivo and ex vivo cancer detection, in real time and without expensive capital equipment or the need for steep clinician learning curves.
“We believe that MarginScan has the potential to be employed in standard of care procedures for the most common cancers in the world. PHC is a collaboration partner that can make this a reality, in skin cancer and beyond.”
PHC is a subsidiary of PHC Group, a company that produces, sells and services solutions across healthcare solutions, diabetes management, and diagnostics and life sciences sector.